经肝动脉化疗栓塞后联合索拉非尼治疗肝癌患者临床观察

doi:10.3969/j.issn.1672-5069.2016.05.028

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (5): 612-613.doi: 10.3969/j.issn.1672-5069.2016.05.028

经肝动脉化疗栓塞后联合索拉非尼治疗肝癌患者临床观察

成陕林, 王超峰

710020 陕西省咸阳市中心医院胃肠外科

收稿日期:2016-03-23 出版日期:2016-09-10 发布日期:2016-10-12
作者简介:成陕林,男,47岁,大学本科,副主任医师。E-mail：chengshanling1969@126.com

Clinical observation of sorafenib in treatment of patients with hepatocellular carcinoma after transarterial chemoembolization

Cheng Shanlin, Wang Chaofeng.

Department of Gastrointestinal Surgery,Central Hospital,Xianyang 712000,Shaanxi Province,China

Received:2016-03-23 Online:2016-09-10 Published:2016-10-12

摘要/Abstract

摘要： 目的探讨索拉非尼联合经肝动脉化疗栓塞术（TACE）治疗肝癌患者的效果。方法选取142例肝癌患者,其中57例接受TACE治疗,47例接受索拉非尼治疗,38例接受索拉非尼联合TACE治疗。在治疗后12 w,评估治疗效果、总生存期（OS）和疾病进展时间（TTP）。结果联合治疗组有效率为26.32%,显著高于TACE组的17.54%或索拉非尼组的19.15%（P<0.05）;联合治疗组疾病控制率为71.05%,显著高于TACE组的57.89%或索拉非尼组的53.19%（P<0.01）;联合治疗组患者OS为8.6 m,显著高于索拉非尼组的6.2 m或TACE组的7.3 m（P<0.05）;联合治疗组TTP为6.7 m,显著高于索拉非尼组的5.1m或TACE组的 5.6 m（P<0.01）。结论索拉非尼联合TACE治疗肝癌患者具有较好的临床效果。

关键词: 肝癌, 索拉非尼, 经肝动脉化疗栓塞术, 疗效

Key words: Hepatocellular carcinoma, Sorafenib, Transarterial chemoembolization, Efficacy

成陕林, 王超峰. 经肝动脉化疗栓塞后联合索拉非尼治疗肝癌患者临床观察[J]. 实用肝脏病杂志, 2016, 19(5): 612-613.

Cheng Shanlin, Wang Chaofeng.. Clinical observation of sorafenib in treatment of patients with hepatocellular carcinoma after transarterial chemoembolization[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 612-613.

参考文献

[1] Shirota N,Saito K,Sugimoto K,et al. Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma:a pilot study. Cancer Imaging,2016,16（1）:1-6.
[2] Vitale A,Burra P,Frigo AC,et al. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages:a multicentre study. Hepatology,2015,62（3）:617-624.
[3] Prajapati HJ,Xing M,Spivey JR,et al. Survival,efficacy,and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. AJR,2014,203（6）:W706-W714.
[4] Gao JJ,Shi ZY,Xia JF,et al. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol,2015,21（42）:12059-12070.
[5] Duffy AG,Ulahannan SV,Cao L,et al. A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. United Eur Gastroenterol,2015,3（5）:453-461.
[6] Newell P,Cottam B,Savage T,et al. Circulating and intratumoral macrophages in patients with hepatocellular carcinoma:correlation with therapeutic approach. Am J Surg,2013,205（5）:534-540.
[7] Abd Elrazek AE,Bilasy SE,Elbanna AE,et al. Prior to the oral therapy,what do we know about HCV-4 in Egypt:a randomized survey of prevalence and risks using data mining computed analysis. Medicine （Baltimore）,2014,93（28）:1-7.
[8] Hao JF,Zhang LW,Bai JX, et al. Incidence,risk factors, and prognosis of acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma:a prospective cohort study. Indian J Cancer,2015,51（Suppl 2）:e3-e8.
[9] Brozzetti S,Bezzi M,De Sanctis GM,et al. Elderly and very elderly patients with hepatocellular carcinoma. Strategy for a first line treatment. Ann Ital Chir,2014,85（2）:120-128.
[10] Golfieri R,Bilbao JI,Carpanese L,et al. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. Hepatology,2013,59（4）:753-761.
[11] Chen J,Zhou C,Long Y,et al. Sunitinib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma:a propensity score matching study. Tumour Biol,2015,36（1）:183-191.
[12] 张明娟,刘佳,向晓星,等. TACE联合索拉非尼治疗晚期肝癌的Meta分析. 中华肿瘤防治杂志,2015,22（2）:148-160.
[13] Cheng AL,Guan Z,Chen Z,et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer,2012,48（10）:1452-1465.
[14] Iavarone M,Cabibbo G,Biolato M,et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology,2015,62（3）:784-791.

[1]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[2]	邢昊, 韩骏, 杨田. 应用血清PIVKA-II诊断肝细胞癌研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 934-937.
[3]	巴正武, 栗海龙, 杨慧. 能谱CT成像定量评估Budd-Chiari综合征患者TIPS术治疗前后肝功能状态临床价值研究*[J]. 实用肝脏病杂志, 2019, 22(5): 680-683.
[4]	刘杏, 赵树立, 张殿隆. 七氟烷吸入时机对肝脏部分切除术患者肝脏缺血再灌注损伤的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 728-731.
[5]	张志成, 袁广庆, 莫灿均. 肝动脉栓塞术治疗三种类型肝血管瘤患者疗效及安全性分析*[J]. 实用肝脏病杂志, 2019, 22(5): 736-739.
[6]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.
[7]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[8]	严玲玲, 胡东辉, 黄艳芳. 腺苷蛋氨酸联合多烯磷酯酰胆碱治疗妊娠期肝内胆汁淤积症患者临床疗效初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 530-533.
[9]	戴青云, 王润东, 荚卫东. 术前预后营养指数评估肝细胞癌患者肝切除术后早期肿瘤复发价值探讨^*[J]. 实用肝脏病杂志, 2019, 22(4): 561-564.
[10]	崔发强, 李涛, 王铮, 陈青. 原发性肝癌患者外周血KRAS基因水平及其对西妥昔单克隆抗体治疗疗效的影响[J]. 实用肝脏病杂志, 2019, 22(4): 565-568.
[11]	王宝丹, 李萌, 高于. α-干扰素治疗慢性乙型肝炎儿童疗效及其影响疗效的因素分析[J]. 实用肝脏病杂志, 2019, 22(3): 345-348.
[12]	袁春晖, 李春雨, 李红丽, 赵红娜, 王文红, 孟庆旭, 张中学. 国产聚乙二醇化干扰素α治疗HBeAg阳性慢性乙型肝炎患者疗效研究[J]. 实用肝脏病杂志, 2019, 22(3): 353-356.
[13]	徐曼曼, 陈煜, 李爽. 特利加压素联合白蛋白输注治疗肝肾综合征患者疗效及尿NGAL和KIM-1对疗效的预测价值[J]. 实用肝脏病杂志, 2019, 22(3): 385-388.
[14]	赵晓光, 史玉洁. 应用还原型谷胱甘肽预防处理接受TACE治疗的中晚期原发性肝癌患者对肝功能的影响[J]. 实用肝脏病杂志, 2019, 22(3): 425-428.
[15]	李克田,沈明格,王凤荣,胡春荣,曹玉杰,芦鹏. 血糖水平对原发性肝癌患者¹⁸F-FDG摄取和PET/CT检查图像质量的影响研究^*[J]. 实用肝脏病杂志, 2019, 22(2): 256-259.

经肝动脉化疗栓塞后联合索拉非尼治疗肝癌患者临床观察

Clinical observation of sorafenib in treatment of patients with hepatocellular carcinoma after transarterial chemoembolization

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价